1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Drugs In Development, 2022, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 16, 7, 2, 61, 44 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 6, 8, 39 and 34 molecules, respectively.
Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Tuberculosis - Overview
- Tuberculosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Tuberculosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tuberculosis - Companies Involved in Therapeutics Development
- Tuberculosis - Drug Profiles
- Tuberculosis - Dormant Projects
- Tuberculosis - Discontinued Products
- Tuberculosis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Tuberculosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Tuberculosis - Dormant Projects, 2022
- Tuberculosis - Discontinued Products, 2022
- Number of Products under Development for Tuberculosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AdjuTec Pharma AS
- Archivel Farma SL
- Astellas Pharma Inc
- AstraZeneca Plc
- Astria Therapeutics Inc
- Atomwise Inc
- Austrianni GmbH
- BioLingus AG
- BioNTech SE
- Bioversys AG
- Bristol-Myers Squibb Co
- C&O Pharmaceutical Technology (Holdings) Ltd
- CanSino Biologics Inc
- Changzhou Yinsheng Pharmaceutical Co Ltd
- Chengdu Keen Biotechnology Co Ltd
- Chongqing Zhifei Biological Products Co Ltd
- Collaborations Pharmaceuticals Inc
- Consegna Pharma Inc
- Crestone Inc
- Daiichi Sankyo Co Ltd
- Demuris Ltd
- Eisai Co Ltd
- Eli Lilly and Co
- Ena Therapeutics Pty Ltd
- Enyo Pharma SA
- EpiVax Inc
- Evotec SE
- Exscientia Plc
- Eyam Vaccines and Immunotherapeutics Ltd
- EyeGene Inc
- Fimbrion Therapeutics Inc
- Gamaleya Federal Research Center of Epidemiology and Microbiology
- GC Biopharma Corp
- Genu Pharma Co Ltd
- Globeimmune Inc
- Greffex Inc
- GSK plc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangzhou Egg Biotechnology Co Ltd
- HanaVax Inc
- Hsiri Therapeutics LLC
- ILiAD Biotechnologies LLC
- Immodulon Therapeutics Ltd
- Immunitor Inc
- ImmunoBiology Ltd
- Innovare R & D SA De CV
- Jiangsu Recbio Technology Co Ltd
- L2 Diagnostics LLC
- Lead Discovery Center GmbH
- LegoChem Biosciences Inc
- MannKind Corp
- Medicines Development for Global Health Ltd
- Merck & Co Inc
- MetalloPharm LLC
- Microbiotix Inc
- Mountain Valley MD Holdings Inc
- Mycosynthetix Inc
- Nearmedic Plus
- Neuro Horizon Pharma LLC
- NovoBiotic Pharmaceuticals LLC
- NTxBio LLC
- Nykode Therapeutics ASA
- Opal Biosciences Ltd
- Otsuka Pharmaceutical Co Ltd
- Pai Life Sciences Inc
- Palisades Therapeutics
- Pathens Inc
- PDS Biotechnology Corp
- PeptiDream Inc
- Pfizer Inc
- Pharmapraxis
- Pharmasyntez
- Primetime Life Sciences LLC
- Protibea Therapeutics Inc
- Quratis Inc
- QureTech Bio AB
- Qurient Co Ltd
- Sanofi
- Sentan Pharma Inc
- Sequella Inc
- Serum Institute of India Pvt Ltd
- Shanghai H&G Biotech
- Shanghai Jiatan Pharmaceutical Technology Co Ltd
- Spero Therapeutics Inc
- Sphaera Pharma Pte Ltd
- Standigm Inc
- Target Medicals
- Tibet Rhodiola Pharmaceutical Holding Co Ltd
- TVAX Biomedical Inc
- Tydock Pharma Srl
- Uvax Bio LLC
- Vaxil Bio Therapeutics Ltd
- Vaxinano SE
- Vaxine Pty Ltd
- Vaxxit Srl
- Vichem Chemie Research Ltd
- Vir Biotechnology Inc
- Zata Pharmaceuticals Inc
